Edition:
India

Unum Therapeutics Inc (UMRX.OQ)

UMRX.OQ on NASDAQ Stock Exchange Global Select Market

4.50USD
21 Mar 2019
Change (% chg)

-- (--)
Prev Close
$4.50
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
63,018
52-wk High
$17.57
52-wk Low
$3.62

Latest Key Developments (Source: Significant Developments)

Unum Therapeutics - Co Entered Amendment To Loan Security Agreement, Dated As Of Jan 19, 2017
Wednesday, 23 Jan 2019 

Jan 23 (Reuters) - Unum Therapeutics Inc ::UNUM THERAPEUTICS - ON JAN 18, CO ENTERED AMENDMENT TO LOAN SECURITY AGREEMENT, DATED AS OF JAN 19, 2017.UNUM THERAPEUTICS - UNDER SECOND AMENDMENT, DRAW DEADLINE WAS EXTENDED TO JUNE 30, 2019.UNUM THERAPEUTICS - UNDER SECOND AMENDMENT, INTEREST ONLY PERIOD EXTENDED TILL JUNE 30, 2020 WITH POTENTIAL ADDITIONAL EXTENSION TO MARCH 31, 2021.UNUM THERAPEUTICS - UNDER SECOND AMENDMENT, A 24-MONTH INTEREST & PRINCIPAL PERIOD EXTENDED TO START FOLLOWING END OF AMENDED INTEREST ONLY PERIOD.  Full Article

Unum Therapeutics Reports Q3 Loss Per Share $0.34
Tuesday, 13 Nov 2018 

Nov 12 (Reuters) - Unum Therapeutics Inc ::UNUM THERAPEUTICS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q3 LOSS PER SHARE $0.34.Q3 EARNINGS PER SHARE VIEW $-0.35 -- THOMSON REUTERS I/B/E/S.UNUM THERAPEUTICS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.AS OF SEPTEMBER 30, 2018, UNUM HAD CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES OF $87.1 MILLION..UNUM THERAPEUTICS - EXISTING CASH, CASH EQUIVALENTS, MARKETABLE SECURITIES WILL FUND OPERATING EXPENSES, CAPEX REQUIREMENTS THROUGH AT LEAST JUNE 2020.QTRLY COLLABORATION REVENUE $2.0 MILLION VERSUS $2.3 MILLION.  Full Article